Singular Genomics Systems's total liabilities is $63M.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
The latest total liabilities for OMIC is $63M as of September 2024. That compares with $85M in the prior-year period — down 26.0% year over year. Investors often review this figure alongside Singular Genomics Systems's historical trend and sector peers before judging valuation or financial health.
Over the past year, OMIC's total liabilities moved from $85M to $63M — a 26.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Singular Genomics Systems's operating scale or balance-sheet position.
A total liabilities figure of $63M for OMIC is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.
After noting OMIC's total liabilities ($63M), review year-over-year change from $85M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Singular Genomics Systems's total liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.